tiprankstipranks
Boston Scientific (GB:0HOY)
LSE:0HOY
UK Market
0HOY
Boston Scientific
RESEARCH TOOLSreports

Boston Scientific (0HOY) Share Forecast & Price Target

5 Followers
See the Price Targets and Ratings of:

0HOY Analyst Ratings

Strong Buy
25Ratings
Strong Buy
24 Buy
1 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Boston
Scientific
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HOY Stock 12 Month Forecast

Average Price Target

$103.95
▲(65.03% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $103.95 with a high forecast of $124.00 and a low forecast of $88.00. The average price target represents a 65.03% change from the last price of $62.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","77":"$77","93":"$93","109":"$109","125":"$125"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,77,93,109,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.502,67.23261538461539,71.96323076923078,76.69384615384615,81.42446153846154,86.15507692307692,90.88569230769231,95.61630769230769,100.34692307692308,105.07753846153847,109.80815384615384,114.53876923076922,119.26938461538461,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.502,65.6903076923077,68.87861538461539,72.06692307692308,75.25523076923078,78.44353846153847,81.63184615384615,84.82015384615386,88.00846153846155,91.19676923076923,94.38507692307692,97.57338461538461,100.76169230769231,{"y":103.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.502,64.46338461538461,66.42476923076923,68.38615384615385,70.34753846153846,72.30892307692308,74.2703076923077,76.23169230769231,78.19307692307693,80.15446153846153,82.11584615384615,84.07723076923077,86.03861538461538,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.598,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.156,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 88,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.852,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.405,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.89,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 97,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.502,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$103.95Lowest Price Target$88.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on GB:0HOY
Matthew Taylor
Jefferies
Jefferies
$110
Buy
74.63%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Alto Neuroscience, Inc. (NYSE: ANRO)
RBC Capital Analyst forecast on GB:0HOY
Shagun Singh Chadha
RBC Capital
RBC Capital
$115
Buy
82.57%
Upside
Reiterated
04/02/26
Boston Scientific (BSX) Receives a Buy from RBC Capital
Erste Group Analyst forecast on GB:0HOY
Hans Engel
Erste Group
Erste Group
―
Hold
―
Assigned
04/01/26
Boston Scientific (BSX) Gets a Hold from Erste Group
Truist Financial Analyst forecast on GB:0HOY
Richard Newitter
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP), Alumis Inc. (NASDAQ: ALMS) and Boston Scientific (NYSE: BSX)
Leerink Partners Analyst forecast on GB:0HOY
Mike Kratky
Leerink Partners
Leerink Partners
$95→$89
Buy
41.29%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on GB:0HOY
Travis Steed
Bank of America Securities
Bank of America Securities
$105
Buy
66.69%
Upside
Reiterated
03/30/26
Boston Scientific: CHAMPION AF Validates Watchman Safety, Supporting 20% LAAC Growth and Buy Rating
Canaccord Genuity Analyst forecast on GB:0HOY
William Plovanic
Canaccord Genuity
Canaccord Genuity
$109
Buy
73.04%
Upside
Reiterated
03/30/26
Boston Scientific (BSX) Gets a Buy from Canaccord Genuity
Wells Fargo Analyst forecast on GB:0HOY
Larry Biegelsen
Wells Fargo
Wells Fargo
$94
Buy
49.23%
Upside
Reiterated
03/30/26
Boston Scientific upside scenario unlikely after data, says Wells FargoBoston Scientific upside scenario unlikely after data, says Wells Fargo
Evercore ISI Analyst forecast on GB:0HOY
Vijay Kumar
Evercore ISI
Evercore ISI
$96
Buy
52.41%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on GB:0HOY
Michael Matson
Needham
Needham
$97
Buy
53.99%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on GB:0HOY
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$90
Buy
42.88%
Upside
Reiterated
03/30/26
Stifel Nicolaus Sticks to Its Buy Rating for Boston Scientific (BSX)
Barclays Analyst forecast on GB:0HOY
Matt Miksic
Barclays
Barclays
$124
Buy
96.86%
Upside
Reiterated
03/29/26
Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen Analyst forecast on GB:0HOY
Josh Jennings
TD Cowen
TD Cowen
$100
Buy
58.76%
Upside
Reiterated
03/29/26
Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
BTIG Analyst forecast on GB:0HOY
Marie Thibault
BTIG
BTIG
$110
Buy
74.63%
Upside
Reiterated
03/29/26
Boston Scientific: Positive on Watchman LAAC as CHAMPION-AF Data Support First-Line Use, Label Expansion, and Upside to Growth
Raymond James Analyst forecast on GB:0HOY
Jayson Bedford
Raymond James
Raymond James
$97→$88
Buy
39.70%
Upside
Reiterated
03/27/26
Boston Scientific downgraded to Outperform from Strong Buy at Raymond JamesBoston Scientific downgraded to Outperform from Strong Buy at Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on GB:0HOY
Matthew Taylor
Jefferies
Jefferies
$110
Buy
74.63%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Alto Neuroscience, Inc. (NYSE: ANRO)
RBC Capital Analyst forecast on GB:0HOY
Shagun Singh Chadha
RBC Capital
RBC Capital
$115
Buy
82.57%
Upside
Reiterated
04/02/26
Boston Scientific (BSX) Receives a Buy from RBC Capital
Erste Group Analyst forecast on GB:0HOY
Hans Engel
Erste Group
Erste Group
―
Hold
―
Assigned
04/01/26
Boston Scientific (BSX) Gets a Hold from Erste Group
Truist Financial Analyst forecast on GB:0HOY
Richard Newitter
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP), Alumis Inc. (NASDAQ: ALMS) and Boston Scientific (NYSE: BSX)
Leerink Partners Analyst forecast on GB:0HOY
Mike Kratky
Leerink Partners
Leerink Partners
$95→$89
Buy
41.29%
Upside
Reiterated
03/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on GB:0HOY
Travis Steed
Bank of America Securities
Bank of America Securities
$105
Buy
66.69%
Upside
Reiterated
03/30/26
Boston Scientific: CHAMPION AF Validates Watchman Safety, Supporting 20% LAAC Growth and Buy Rating
Canaccord Genuity Analyst forecast on GB:0HOY
William Plovanic
Canaccord Genuity
Canaccord Genuity
$109
Buy
73.04%
Upside
Reiterated
03/30/26
Boston Scientific (BSX) Gets a Buy from Canaccord Genuity
Wells Fargo Analyst forecast on GB:0HOY
Larry Biegelsen
Wells Fargo
Wells Fargo
$94
Buy
49.23%
Upside
Reiterated
03/30/26
Boston Scientific upside scenario unlikely after data, says Wells FargoBoston Scientific upside scenario unlikely after data, says Wells Fargo
Evercore ISI Analyst forecast on GB:0HOY
Vijay Kumar
Evercore ISI
Evercore ISI
$96
Buy
52.41%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham Analyst forecast on GB:0HOY
Michael Matson
Needham
Needham
$97
Buy
53.99%
Upside
Reiterated
03/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on GB:0HOY
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$90
Buy
42.88%
Upside
Reiterated
03/30/26
Stifel Nicolaus Sticks to Its Buy Rating for Boston Scientific (BSX)
Barclays Analyst forecast on GB:0HOY
Matt Miksic
Barclays
Barclays
$124
Buy
96.86%
Upside
Reiterated
03/29/26
Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen Analyst forecast on GB:0HOY
Josh Jennings
TD Cowen
TD Cowen
$100
Buy
58.76%
Upside
Reiterated
03/29/26
Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth
BTIG Analyst forecast on GB:0HOY
Marie Thibault
BTIG
BTIG
$110
Buy
74.63%
Upside
Reiterated
03/29/26
Boston Scientific: Positive on Watchman LAAC as CHAMPION-AF Data Support First-Line Use, Label Expansion, and Upside to Growth
Raymond James Analyst forecast on GB:0HOY
Jayson Bedford
Raymond James
Raymond James
$97→$88
Buy
39.70%
Upside
Reiterated
03/27/26
Boston Scientific downgraded to Outperform from Strong Buy at Raymond JamesBoston Scientific downgraded to Outperform from Strong Buy at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months
xxx
Success Rate
18/24 ratings generated profit
75%
Average Return
+5.52%
reiterated a xxx
 rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.52% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
41/54 ratings generated profit
76%
Average Return
+14.69%
reiterated a buy rating 10 days ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 75.93% of your transactions generating a profit, with an average return of +14.69% per trade.
2 Years
xxx
Success Rate
43/54 ratings generated profit
80%
Average Return
+29.44%
reiterated a xxx
 rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 79.63% of your transactions generating a profit, with an average return of +29.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HOY Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
1
5
15
14
Buy
61
38
69
82
58
Hold
2
4
18
28
25
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
63
43
92
125
97
In the current month, 0HOY has received 72 Buy Ratings, 25 Hold Ratings, and 0 Sell Ratings. 0HOY average Analyst price target in the past 3 months is 103.95.
Each month's total comprises the sum of three months' worth of ratings.

0HOY Financial Forecast

0HOY Earnings Forecast

Next quarter’s earnings estimate for 0HOY is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. 0HOY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HOY is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. 0HOY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.

0HOY Sales Forecast

Next quarter’s sales forecast for 0HOY is $5.18B with a range of $5.08B to $5.28B. The previous quarter’s sales results were $5.29B. 0HOY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HOY is $5.18B with a range of $5.08B to $5.28B. The previous quarter’s sales results were $5.29B. 0HOY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.

0HOY Stock Forecast FAQ

What is GB:0HOY’s average 12-month price target, according to analysts?
Based on analyst ratings, Boston Scientific’s 12-month average price target is 103.95.
    What is GB:0HOY’s upside potential, based on the analysts’ average price target?
    Boston Scientific has 65.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Boston Scientific a Buy, Sell or Hold?
          Boston Scientific has a consensus rating of Strong Buy, which is based on 24 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Boston Scientific’s share price target?
            The average share price target for Boston Scientific is 103.95. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $124.00 ,and the lowest forecast is $88.00. The average share price target represents 65.03% Increase from the current price of $62.99.
              What do analysts say about Boston Scientific?
              Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of Boston Scientific?
                To buy shares of GB:0HOY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.